All pages
Powered by GitBook
1 of 1

Loading...

Drug Extension Authoring

Model-Driven and Scalable Authoring

Drug extension content is not typically authored manually on a concept-by-concept basis. Instead, it is derived from existing national drug dictionaries using a structured and scalable process.

This approach is comparable to the development of terminologies such as LOINC, where content is generated based on combinations of well-defined attributes.

Process

1

Mapping Atomic Components

The process begins with mapping the atomic elements of the local drug dictionary to SNOMED CT and related standards. These include:

  • substances (active ingredients)

  • dose forms

  • units of measure

  • strength representations

SNOMED CT aligns with EDQM (European Directorate for the Quality of Medicines) standards for dose forms. Where local dictionaries also use EDQM, this significantly facilitates mapping and interoperability.

2

Once atomic elements are mapped, higher-level drug concepts are generated based on combinations identified in the local dictionary.

These include:

  • Medicinal Products (MP)

  • Medicinal Product Forms (MPF)

3

During concept generation:

  • Existing concepts in the International Edition (MP, MPF, CD) should be reused wherever available

  • Missing concepts are created in the national extension

  • These missing concepts may later be submitted for promotion to the International Edition

4

The generation process is typically implemented as:

  • an automated bulk creation process

  • followed by manual review and quality assurance

This hybrid approach balances scalability with clinical and terminological accuracy.

Drug extension development involves several common challenges, including:

  • Variations in ingredient representation across local dictionaries

  • Limited granularity in source data (e.g. missing strength or form details)

  • Rounding rules for strength normalization

  • Non-normalized strength expressions, including numerator/denominator inconsistencies

Addressing these challenges requires careful normalization and alignment with the SNOMED CT concept model.

Clinical Drugs (CD)
  • Real Clinical Drugs (RCD)

  • Packaged Clinical Drugs (PCD)

  • Real Packaged Clinical Drugs (RPCD)

  • Concepts are typically created algorithmically, using rules derived from the SNOMED CT concept model.

    This ensures consistency while allowing extensions to meet immediate national requirements.

    Differences in units of measure and representation conventions

    Deriving Drug Concepts

    Reuse and Gap Filling

    Validation and Refinement

    Typical Authoring Challenges

    Provide Feedback